Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026
Globe Newswire•04/11/2026•08:00 ET
0
Key Highlights
- ➤Elraglusib oral tablet significantly inhibited tumor growth in aggressive B16F10 melanoma models
- ➤Elraglusib increased intratumoral CD8+ T cells and natural killer cells
- ➤Phase 1/2 oral elraglusib trial planned to begin in Q1 2027
- ➤FDA cleared Actuate’s investigational new drug application in May 2026
Expert Statements
Daniel Schmitt, President and Chief Executive Officer of Actuate Therapeutics
“This preclinical work further supports the mechanism of action for elraglusib and demonstrates that the higher exposures achieved with daily dosing of the Elraglusib Oral Tablet elicit direct antitumor activity and favorable immune cell dynamics within the tumor microenvironment, leading to robust inhibition of tumor growth in this aggressive B16F10 melanoma model.”
Daniel Schmitt, President and Chief Executive Officer of Actuate Therapeutics
“We believe these findings, including the reduction of myeloid-mediated immune suppression that makes poorly immunogenic tumors difficult to treat, support advancing elraglusib tablets into clinical studies as a single agent in patients with refractory metastatic melanoma.”
- Oral tablet formulation of elraglusib as a monotherapy significantly inhibited tumor growth and enhanced antitumor immune activity in an aggressive, poorly immunogenic melanoma model
- Phase 1/2 clinical trial evaluating Elraglusib Oral Tablet to be initiated in Q1 2027
Get started
Create a free account to read the full story.